Moderna’s Mixed Performance: Strong Spikevax Sales Drive Q3 Success Amid mRESVIA Uncertainties, Resulting in Hold Rating
Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...
FiercePharma3d
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
BioSpace3d
Moderna Gets Better-Than-Expected Q3 COVID-19 Vaccine Sales, but RSV Shot Disappoints
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
Moderna posts surprise profit as COVID vaccine sales exceed expectations
Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...
Moderna swings to profits as new COVID shot powers Q3 beat
Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...
Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial ...
The Associated Press on MSN2d
When's the Best Time to Get Your Flu and COVID Shots?
Yes, you can get your flu and COVID-19 shots at the same time. Don't call them boosters -- they're not just another dose of ...
Zacks.com on MSN3d
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View
MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion ...
Moderna EPS Beats Estimates, Sales Rise
Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...
The Motley Fool on MSN3d
These Are the 5 Worst-Performing Stocks in the S&P 500 With 2024 Almost Over
The bottom five are (in order from steepest price decline to narrowest): Walgreens Boots Alliance (NASDAQ: WBA), Estée Lauder ...
Moderna price target lowered to $111 from $125 at Barclays
Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...
Moderna is a ‘show-me story’ heading into Q3 earnings
Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...